
Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
The SOHO-01 study evaluated the efficacy and safety of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer across multiple cohorts.
The SOHO-01 study evaluated the efficacy and safety of sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer across multiple cohorts. Results showed durable antitumor activity and manageable safety profiles in both previously treated and treatment-naive patients. Additionally, the therapy demonstrated intracranial activity in patients presenting with active brain metastases.





